Fig. 2

In vivo evaluation of ENT and VCR in eRMS and pleoRMS patient-derived xenograft. a–g Graphical analysis of four different PDX eRMS and three different PDX pleoRMS mice models (Champions Oncology and The Jackson Laboratory) established from clinical biopsies, recurrent eRMS, or autopsies male/female with eRMS. Detailed patient history of these eRMS and pleoRMS models is given in Additional file 6: Table S2 & S8 respectively. Mice were treated with vehicle, ENT (4 mg/kg or 5 mg/kg), and vincristine (0.75 mg/kg) as single agents and in combination in each treatment groups and average tumor volume were plotted until the end-point of the experiment. Detailed treatment schedules are given in Additional file 6: Table S1. Statistical summary for the response to treatment is given in Additional file 6: Table S4–S6 for eRMS PDX models and in Additional file 6: Table S9–S11 for pleoRMS. Effectiveness of VCR precluded drawing any conclusions of ENT-VCR combination therapy in eRMS models